Liraglutide, a relatively novel incretin mimetic from the glucagon-like peptide-1 (GLP-1) analog class of anti-obesity and anti-type 2 diabetes (T2D) medications, has been previously reported to result in significant weight reduction in patients
Telogen effluvium is frequently observed in patients undergoing significant weight loss, such as following metabolic or bariatric surgery [84, 85]
Ozempic and Rybelsus are not FDA approved to treat type 2 diabetes
Quinine: This compound, famously found in tonic water, can cause a severe, rapid drop in platelets in sensitive individuals
In this behavioral task, a lower alternation percentage is considered as a working memory deficit
The RDA for infants hasnt been established